Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRP - RegenKit-BCT-3 Plus
- Development stage
- Unknown
- Lead developer
- Regen Lab
- Modality
- Cell Therapies
- Administration
- Parenteral
01
Overview
PRP - RegenKit-BCT-3 Plus is an autologous platelet-rich plasma (PRP) preparation system developed by Regen Lab SA and evaluated by Boston Medical Group for the treatment of erectile dysfunction (ED). Prepared using the RegenKit BCT (Blood Cell Therapy) platform, the system utilizes three individually packaged tubes to isolate and concentrate platelets from a patient's peripheral blood, yielding a therapeutic PRP solution. Administered via intracavernous injection, the therapy delivers a high concentration of autologous growth factors—including VEGF, PDGF, TGF-β, FGF, and EGF—directly to the penile corpora cavernosa. These growth factors bind to their respective receptors to stimulate angiogenesis, tissue remodeling, and nerve regeneration, thereby restoring erectile function. The therapy is currently being evaluated in a Phase 3 randomized, placebo-controlled clinical trial in Spain for men with moderate or mild-to-moderate erectile dysfunction.
- Brand names
- RegenKit-BCT-3 PlusRegenKit-BCT3 PlusRegenKit-BCT 3 PlusRegenKit-BCT-3RegenKit-BCT3RegenKit-BCT 3
- Other names
- PRP - RegenKit-BCT-3 PlusBostonPRPautologous platelet-rich plasma
Beyond the preview
Go deeper on PRP - RegenKit-BCT-3 Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRP - RegenKit-BCT-3 Plus.